Table 2. Percentage of NMJs labeled with anti-NF-L, -synaptophysin, -S100B, -GFAP or -p75NTR in EOMs of ALS and controls.
| Donors | NF-L | SYP | S100B | GFAP | p75NTR |
| D1 | 76% (N = 21) | 82% (N = 11) | 37% (N = 57) (6%–69%)a | 100% (N = 41) | 70% (N = 40) |
| D2 | 76% (64%–87%) (N = 215) | 84% (74%–91%) (N = 79) | 10% (N = 74) | 89% (N = 52) | 83% (N = 23) |
| D4 | 88% (67) | 91% (N = 85) (86%–95%) | 30% (N = 74) (27%–34%) | 95% (N = 49) (91%–100%) | 93% (N = 59) (93%–94%) |
| D5 | 90% (N = 19) | 88% (N = 32) | 20% (N = 50) | 91% (N = 44) | 89% (N = 35) |
| D7 | 69% (N = 13) | 80% (N = 20) | 19% (N = 171) (6%–43%) | 93% (N = 112) (83%–100%) | 89% (N = 117) (84%–92%) |
| Mean±SE | 77%±3.5 (N = 357) | 85%±2.3 (N = 380) | 25%±7.1* (N = 426) | 94%±2.4 (N = 298) | 87%±2.8 (N = 274) |
| Controls | |||||
| Adult (n = 5) | 82%±5.4 (N = 206) | 88%±1.5 (N = 260) | 78%±11.8 (N = 264) | 94%±2.5 (N = 131) | 92%±5.6 (N = 127) |
| Elderly (n = 5) | 80%±4.0 (N = 92) | 84%±2.9 (N = 143) | 82%±3.9 (N = 66) | 100%±0 (N = 40) | 87%±13.3 (N = 45) |
a
The range of the percentage of the labeled NMJs is given when more than one muscle specimen from the same donor was examined.
*
Statistically significant difference between ALS donors and elderly (p = 0.005), and adult (p = 0.01) controls.
N: the number of NMJs examined; n: the number of control subjects studied.